|
|||||
|
|
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist,tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes |
|
| Authors: | Jonathan M. Wilson PhD Amir Nikooienejad PhD Deborah A. Robins MS William C. Roell PhD Jeffrey S. Riesmeyer MD Axel Haupt MD Kevin L. Duffin PhD Marja-Riitta Taskinen MD Giacomo Ruotolo MD |
| Affiliation: | 1. Eli Lilly and Company, Indianapolis, Indiana, USA;2. Research Program for Clinical and Molecular Medicine Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland |
| Abstract: | |
| Keywords: | incretin therapy type 2 diabetes |